Literature DB >> 28853097

Application of Tetrameric Recombinant Human Butyrylcholinesterase as a Biopharmaceutical for Amelioration of Symptoms of Acute Organophosphate Poisoning.

S S Terekhov1, V A Palikov2, Y A Palikova2, I A Dyachenko2, O G Shamborant3, I V Smirnov3, P Masson4, A G Gabibov3.   

Abstract

We present a procedure for optimizing the expression of recombinant tetrameric butyrylcholinesterase that enables large-scale production with the yield >30 mg/liter (>90 mg/roller bottle). Intravenous injection of the preparation significantly increased survival and decreased the severity of symptoms of poisoning with paraoxon, an organophosphorus toxin.

Entities:  

Keywords:  biological drug; organophosphate toxins; paraoxon; prevention of poisoning; tetrameric recombinant human butyrylcholinesterase

Mesh：

Substances：

Year:  2017        PMID： 28853097     DOI： 10.1007/s10517-017-3821-z

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN： 0007-4888            Impact factor:   0.804


  1 in total

Review 1.  Trends in the Recent Patent Literature on Cholinesterase Reactivators (2016-2019).

Authors:  Alexandre A de Castro; Letícia C Assis; Flávia V Soares; Kamil Kuca; Daniel A Polisel; Elaine F F da Cunha; Teodorico C Ramalho
Journal:  Biomolecules       Date:  2020-03-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.